Correction: Efficacy, safety, and patient-reported outcome of immune checkpoint inhibitor in gynecologic cancers: A systematic review and meta-analysis of randomized controlled trials

Correction: Efficacy, safety, and patient-reported outcome of immune checkpoint inhibitor in gynecologic cancers: A systematic review and meta-analysis of randomized controlled trials

Saved in:

Bibliographic Details
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2024-01-01
Series:	PLoS ONE
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11684688/?tool=EBI
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Correction: Efficacy, safety, and patient-reported outcome of immune checkpoint inhibitor in gynecologic cancers: A systematic review and meta-analysis of randomized controlled trials.
by: Fitriyadi Kusuma, et al.
Published: (2024-01-01)

Efficacy and safety of immune checkpoint inhibitors in patients with advanced intrahepatic cholangiocarcinoma
by: Ziting Peng, et al.
Published: (2025-02-01)

Immune checkpoint inhibitors in cancer patients with autoimmune disease: Safety and efficacy
by: Jiayuan Le, et al.
Published: (2025-12-01)

The implementation and side effect management of immune checkpoint inhibitors in gynecologic oncology: a JAGO/NOGGO survey
by: Maximilian Riedel, et al.
Published: (2025-01-01)

The safety and efficacy of immune checkpoint blockade in children, adolescents, and young adults: A systematic review and meta-analysis
by: Pedro C.A. Reis, et al.
Published: (2025-06-01)

Efficacy and safety of immune checkpoint inhibitors in elderly patients with advanced non-small cell lung cancer: a systematic review and meta-analysisResearch in context
by: Jiacheng Yao, et al.
Published: (2025-03-01)

Safety and efficacy of immune checkpoint inhibitors in patients with pre-treatment reduced left ventricular function
by: Maor Tzuberi, et al.
Published: (2025-01-01)

Cancer type-specific adverse events of immune checkpoint inhibitors: A systematic review and meta-analysis
by: Xuhui Tong, et al.
Published: (2025-01-01)

Clinical utility of tumour mutational burden on efficacy of immune checkpoint inhibitors in malignant solid tumours: protocol for a systematic review and meta-analysis
by: Xiaoguang Yang, et al.
Published: (2022-08-01)

Efficacy and safety of cardiac myosin inhibitors for symptomatic hypertrophic cardiomyopathy: a meta-analysis of randomized controlled trials
by: Anas Abunada, et al.
Published: (2025-01-01)

Immune Checkpoint Inhibitors +/− Chemotherapy for Patients With NSCLC and Brain Metastases: A Systematic Review and Network Meta‐Analysis
by: Lauren Julia Brown, et al.
Published: (2025-01-01)

Inosine enhances the efficacy of immune‐checkpoint inhibitors in advanced solid tumors: A randomized, controlled, Phase 2 study
by: Haiqing Zhao, et al.
Published: (2024-09-01)

Comparative efficacy and safety of first-line neoadjuvant therapy for early-stage non-small cell lung cancer based on immune checkpoint inhibitor therapy: a systematic review and network meta-analysis
by: Linfeng Wang, et al.
Published: (2025-01-01)

Association of hepatitis B virus DNA levels with efficacy and safety and the impact of antiviral therapy on prognosis in liver cancer patients receiving immune checkpoint inhibitors therapy: a systematic review and meta-analysis
by: Hongxia Cui, et al.
Published: (2025-01-01)

Efficacy and Safety Evaluation of Immune Checkpoint Inhibitors in Combination With Chemotherapy for Extensive Small Cell Lung Cancer: Real‐World Evidence
by: Yuta Yamanaka, et al.
Published: (2024-12-01)

Subacute parkinsonism induced by immune checkpoint inhibitors
by: Lénia Silva, et al.
Published: (2024-12-01)

Treatment Options for Advanced Non-Small Cell Lung Cancer After Failure of Previous Immune Checkpoint Inhibitors and Chemotherapy: Meta-Analysis of Five Randomized Controlled Trials
by: Andrea Messori, et al.
Published: (2025-01-01)

Unleashing immunity against oral cancer with immune checkpoint inhibitors
by: Ajay Guru
Published: (2024-06-01)

The efficacy and safety of Vonoprazan and Tegoprazan in eradication: a comprehensive systematic review and meta-analysis of randomized controlled trials
by: Ting Jin, et al.
Published: (2025-01-01)

Efficacy and safety of anticoagulants on venous thromboembolism: a systematic review and network meta-analysis of randomized controlled trials
by: Weijie Fu, et al.
Published: (2025-01-01)

Clinical outcomes of endocrine and other disorders induced by immune checkpoint inhibitors in Japanese patients
by: Yuichiro Iwamoto, et al.
Published: (2025-01-01)

From chaos to order: optimizing fecal microbiota transplantation for enhanced immune checkpoint inhibitors efficacy
by: Anqi Lin, et al.
Published: (2025-12-01)

Resistance mechanisms to immune checkpoint inhibitors: updated insights
by: Besan H. Alsaafeen, et al.
Published: (2025-01-01)

A review of neurological complications of immune-checkpoint inhibitors
by: D. Valančius, et al.
Published: (2021-12-01)

The efficacy and safety of fluvoxamine in patients with COVID-19: A systematic review and meta-analysis from randomized controlled trials.
by: Qiufeng Zhou, et al.
Published: (2024-01-01)

Efficacy and safety of intermittent fasting for type 2 diabetes mellitus: A systematic review and meta-analysis of randomized trials
by: Joshua Chadwick, et al.
Published: (2025-01-01)

The prognostic value of circulating tumor DNA in malignant melanoma patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis
by: Lei Liu, et al.
Published: (2025-01-01)

Haemophagocytic lymphohistiocytosis in patients treated with immune checkpoint inhibitors: analysis of WHO global database of individual case safety reports
by: Alessandro Ceschi, et al.
Published: (2019-05-01)

Impact of Immune Checkpoint Inhibitors and Local Radical Treatment on Survival Outcomes in Synchronous Oligometastatic NSCLC
by: Mandy Jongbloed, MD, et al.
Published: (2025-03-01)

Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of lung
by: Samuel Kareff, et al.
Published: (2021-02-01)

Peripheral blood cell counts as predictors of immune-related adverse events in cancer patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis
by: Xinyu Zhang, et al.
Published: (2025-01-01)

The effect of baseline versus early glucocorticoid use on immune checkpoint inhibitor efficacy in patients with advanced NSCLC
by: Yifan Wang, et al.
Published: (2025-01-01)

Meta-Analysis of Randomized Trials: Efficacy and Safety of Colchicine for Secondary Prevention of Cardiovascular Disease
by: Elie Akl, et al.
Published: (2024-01-01)

Efficacy and Safety of Bevacizumab in the Treatment of Pterygium: An Updated Meta-Analysis of Randomized Controlled Trials
by: Yi Sun, et al.
Published: (2018-01-01)

Inflamed immune phenotype predicts favorable clinical outcomes of immune checkpoint inhibitor therapy across multiple cancer types
by: Jeanne Shen, et al.
Published: (2024-02-01)

Efficacy and safety of PD-1/PD-L1 inhibitors in advanced or recurrent endometrial cancer: a meta-analysis with trial sequential analysis of randomized controlled trials
by: Ji Ren, et al.
Published: (2025-01-01)

Multiple stellate keratitis during immune checkpoint inhibitor therapy
by: Isana Nakajima, et al.
Published: (2025-03-01)

Clinical outcomes after immune checkpoint inhibitor-associated acute kidney injury: a cohort study
by: Vin-Cent Wu, et al.
Published: (2025-02-01)

Safety, Immunogenicity, and Efficacy of Cytomegalovirus Vaccines: A Systematic Review of Randomized Controlled Trials
by: Manuela Chiavarini, et al.
Published: (2025-01-01)

Gut Microbiota–Tumor Microenvironment Interactions: Mechanisms and Clinical Implications for Immune Checkpoint Inhibitor Efficacy in Cancer
by: Said SS, et al.
Published: (2025-01-01)